{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:38:54Z","timestamp":1791459534126,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":298,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["GR-2013-02356771 to VG"],"award-info":[{"award-number":["GR-2013-02356771 to VG"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Plan Estatal de Investigacion Cientifica","award":["PI16\/00904 to AP"],"award-info":[{"award-number":["PI16\/00904 to AP"]}]},{"name":"Banco Bilbao Vizcaya Argentaria Foundation"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1093\/annonc\/mdz055","type":"journal-article","created":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T23:21:10Z","timestamp":1550445670000},"page":"921-926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["De-escalated therapy for HR+\/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study"],"prefix":"10.1016","volume":"30","author":[{"given":"V.","family":"Guarneri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-9861","authenticated-orcid":false,"given":"M.V.","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Frassoldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.V.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Orvieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ambroggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-4509","authenticated-orcid":false,"given":"G.","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-5344","authenticated-orcid":false,"given":"P.F.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9938","key":"10.1093\/annonc\/mdz055_bb0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"9816","key":"10.1093\/annonc\/mdz055_bb0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"16","key":"10.1093\/annonc\/mdz055_bb0020","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study","volume":"30","author":"Guarneri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz055_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz055_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-012-2067-8","article-title":"Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers","volume":"135","author":"Nahta","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1093\/annonc\/mdz055_bb0035","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000354253","article-title":"Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications","volume":"8","author":"Giuliano","year":"2013","journal-title":"Breast Care (Basel)"},{"issue":"4","key":"10.1093\/annonc\/mdz055_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdz055_bb0045","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: tBCRC 006","volume":"31","author":"Rimawi","year":"2013","journal-title":"JCO"},{"issue":"2","key":"10.1093\/annonc\/mdz055_bb0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"31","key":"10.1093\/annonc\/mdz055_bb0055","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update","volume":"31","author":"Wolff","year":"2013","journal-title":"JCO"},{"issue":"28","key":"10.1093\/annonc\/mdz055_bb0060","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"JCO"},{"issue":"17","key":"10.1093\/annonc\/mdz055_bb0065","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz055_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/annonc\/mds238","article-title":"A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative","volume":"24","author":"Brouckaert","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz055_bb0075","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz055_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdz055_bb0085","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"Harbeck","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz055_bb0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2015-0138","article-title":"Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer","volume":"20","author":"Guarneri","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1093\/annonc\/mdz055_bb0095","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/annonc\/mdw197","article-title":"PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab","volume":"27","author":"Loibl","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz055_bb0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-017-0806-9","article-title":"Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer","volume":"19","author":"Bianchini","year":"2017","journal-title":"Breast Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/6\/921\/28871778\/mdz055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:06:12Z","timestamp":1668693972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419311937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0923753419311937"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz055","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalated therapy for HR+\/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdz055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}